SATB2 and colorectal carcinoma: Given that hypermethylation of SATB2 suppresses its mRNA expression in CRC tissues and that AZA effectively enhances SATB2 expression in certain CRC cell lines, SATB2 has the potential to be a therapeutic target for particular CRC patients.